HC Wainwright Forecasts Evommune’s Q3 Earnings (NYSE:EVMN)

Evommune, Inc. (NYSE:EVMN) – Investment analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Evommune in a research note issued to investors on Friday, August 7th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.91) per share for the quarter, down from their prior estimate of ($0.70). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Evommune’s current full-year earnings is ($2.83) per share. HC Wainwright also issued estimates for Evommune’s Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.41) EPS, Q1 2027 earnings at ($0.97) EPS, Q2 2027 earnings at ($1.01) EPS, Q3 2027 earnings at ($1.05) EPS, Q4 2027 earnings at ($1.11) EPS and FY2027 earnings at ($4.14) EPS.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.21).

Several other analysts have also commented on EVMN. Royal Bank Of Canada dropped their price objective on Evommune from $30.00 to $29.00 and set an “outperform” rating on the stock in a report on Friday. Weiss Ratings downgraded Evommune from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Wall Street Zen lowered Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Morgan Stanley dropped their price target on shares of Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 30th. Finally, William Blair lowered shares of Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Evommune has an average rating of “Moderate Buy” and an average target price of $43.25.

Evommune Trading Down 0.4%

NYSE EVMN opened at $14.03 on Tuesday. The stock has a market capitalization of $505.33 million and a price-to-earnings ratio of -1.27. Evommune has a twelve month low of $10.47 and a twelve month high of $33.20. The stock has a 50-day moving average of $15.84 and a 200 day moving average of $21.17.

Hedge Funds Weigh In On Evommune

Several hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Evommune in the fourth quarter worth about $34,000. Strs Ohio purchased a new stake in Evommune during the 1st quarter valued at about $41,000. The Manufacturers Life Insurance Company acquired a new stake in Evommune in the 4th quarter valued at about $179,000. XTX Topco Ltd acquired a new stake in Evommune in the 4th quarter valued at about $321,000. Finally, Oxford Asset Management LLP purchased a new position in Evommune in the 4th quarter worth approximately $335,000.

Insider Transactions at Evommune

In related news, CEO Luis C. Pena sold 7,438 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total transaction of $168,916.98. Following the completion of the sale, the chief executive officer directly owned 630,458 shares in the company, valued at approximately $14,317,701.18. The trade was a 1.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David E. Cohen sold 6,056 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $20.33, for a total value of $123,118.48. Following the completion of the transaction, the director directly owned 17,609 shares of the company’s stock, valued at approximately $357,990.97. This represents a 25.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 100,854 shares of company stock valued at $2,279,142. Insiders own 31.10% of the company’s stock.

Evommune News Roundup

Here are the key news stories impacting Evommune this week:

• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $3.41 from $2.77 and reduced its FY2027 forecast to a loss of $4.14 from $3.33. The firm also lowered estimates for each reported quarter from Q3 2026 through Q4 2027, signaling expectations for deeper or more prolonged losses.
• Negative Sentiment: The quarterly estimate reductions were substantial: Q3 2026 EPS moved to a loss of $0.91 from $0.70, Q4 2026 to $0.94 from $0.74, Q1 2027 to $0.97 from $0.77, Q2 2027 to $1.01 from $0.82, Q3 2027 to $1.05 from $0.86, and Q4 2027 to $1.11 from $0.90. These changes point to weaker near-term earnings expectations.
• Negative Sentiment: Royal Bank of Canada lowered its price target for Evommune to $29, adding to the cautious analyst outlook. Royal Bank Of Canada Cuts Evommune Price Target

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.